Overview

Effect of Metformin, Dapagliflozin, Combination of Metformin and Pioglitazone in Patients With Type 2 Diabetes

Status:
Not yet recruiting

Trial end date:
2023-02-01

Target enrollment:

Participant gender:

Summary

Although, a number of drugs are promising treatment strategies for insulin resistance, a critical question arises to which drug benefits patients with type 2 diabetes more from reduced insulin resistance and consequent glycemic control. In this study, we aim to evaluate the effect of metformin, dapagliflozin and the fixed-dose combination of metformin and pioglitazone (500mg metformin plus 15mg pioglitazone) on insulin sensitivity and glycemic control in overweight patients with newly diagnosed type 2 diabetes.

Phase:

Phase 3

Details

Lead Sponsor:

Nanjing First Hospital, Nanjing Medical University

Treatments:

Dapagliflozin
Metformin
Pioglitazone